Diabetes and kidneys;Diabetes und Niere

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 18, 2013, Pages 949-955

  Gackler D ^a   Jakel S ^a   Fricke, L ^a   Reinsch, B ^a   Fischer, F ^a  

^a Praxis für Nierenerkrankungen und Diabetes Bochum ^*  (Germany)

Author keywords

cardiovascular risk; diabetic nephropathy; multifactorial intervention; stages of diabetic kidney disease

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; KIDNEY; MALE; NONHUMAN; RAT;

ADULT; ALBUMINURIA; CARDIOVASCULAR DISEASES; CHILD; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EUROPE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS;

EID: 84876836147     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1332992     Document Type: Article

References (49)

1. Adler A. I., Stevens R. J., Manley S. E. et al. Development and progression of nephropathy in type 2 diabetes, The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney international: 2003; 63 225 232 (Pubitemid 35463925)
2. Bakris G. L., Sarafidis P. A., Weir M. R. Renal outcomes with different fixed-dose combination therapies in patients with high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet: 2010; 375 1173 81
3. Bardoxolon methyl evaluation in patients with chronic kidney disease and typ 2 diabetes (BEACON). ClinicalTrials.gov Identifier: NCT01351675
4. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol: 2006; 17 S 132 S 135
5. Bash L. D., Selvin E., Steffes M. et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy. Arch Intern Med: 2008; 168 2440 2447
6. Cohen Tervaert T. W., Mooyaart A. L., Amann K. et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol: 2010; 21 556 563
7. Collins A. J., Foley R. N., Chavers B. et al. US renal data system 2011 annual data report. Am J Kidney Dis: 2012; 59 01 e 1 e 420
8. Deutsche Hochdruckliga e.v. DHL/Deutsche Hypertonie Gesellschaft, Kommission Diabetes Zielblutdruckwerte bei Patienten mit Diabetes mellitus. Stellungnahme vom 7. September: 2010
9. Fox C. S., Matsushita K., Woodward M. et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet: 2012; 380 1662 73
10. Finne P., Reunanen A., Stenman S. et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA: 2005; 294 1782 1787 (Pubitemid 41434624)
11. Frei U., Schober-Halstenberg H-J. Nierenersatztherapie in Deutschland, Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. http://www.bundesverband-niere.de/files/QuaSi-Niere-Bericht-2006- 2007.pdf (Letzter Zugriff: 25.2.2013)
12. Fresenius Medical Care (EuCliD) Zentrumspezifischer Bericht zum erweiterten Benchmarking. Gemeinschaftspraxis Dres. Gäckler/Jäkel/ Fricke/Reinsch (20977), 3. Quartal: 2012; http://www.dialyse-bochum.de/wb/media/ download-gallery/20977-USRReport%20(3)3Q2012.pdf (Letzter Zugriff: 25.2.2013)
13. Gaede P., Lund-Andersen H., Parving H. H. et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med: 2008; 358 580 591 (Pubitemid 351214285)
14. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med: 2003; 348 383 393 (Pubitemid 36159355)
15. Gambaro G., Kinalska I., Oksa A. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients. J Am Soc Nephrol: 2002; 13 1615 1625 (Pubitemid 34579250)
16. Hasslacher C., Wolf G., Kempe P. et al. Diabetische Nephropathie, Praxisempfehlungen der Deutschen Diabetes Gesellschaft. Diabetologie: 2012; 7 99 S102
17. Inker L. A., Schmid C. H., Tighiouart H. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Eng J Med: 2012; 367 20 29
18. Kidney Disease Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney inter Suppl: 2012; 2 337 414
19. Kim M. J., Frankel A. H., Donaldson M. et al. Oral cholecalciferol decreases albuminuria and urinary TGF-Beta 1 in patients with type2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney int: 2011; 80 851 860
20. Klein R., Zinman B., Gardiner R. et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients. Diabetes: 2005; 54 527 533
21. Levey A. S., Bosch J. P., Breyer Lewis J. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med: 1999; 130 461 470 (Pubitemid 29135798)
22. Levey A. S., de Jong P., Coresh J. et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int: 2011; 80 17 28
23. Levey A. S., Stevens L. A., Schmid C. H. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med: 2009; 150 604 612
24. Lipmann-Grob B., Bierwirth R. A., Kron P. et al. Patientenklassifikation und Risikoprofilanalysen bei Typ-2-Diabetikern in der Schwerpunktpraxis. Dtsch Med Wochenschr: 2004; 129 75 81 (Pubitemid 38121819)
25. Lüders S., Franz I. W., Hilgers K. F. et al. Langzeitblutdruckmessung, Statement der Deutschen Hochdruckliga e.V. DHL (Deutsche Hypertonie Gesellschaft), Sektion Hochdruck-Diagnostik. Dtsch Med Wochenschr: 2005; 130 2664 2668 (Pubitemid 41727543)
26. Mann J. FE, Schmieder R. E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind-controlled trial. Lancet: 2008; 372 547 53
27. Matsushita K., Mahmoodi B. K., Woodward M. et al. Comparison of risk prediction using the CKD-Epi equation and the MDRD study equation for Estimated glomerular filtration rate. JAMA: 2012; 307 1941 1951
28. Moen M. F., Zhan M., Hsu V. D. et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol: 2009; 4 1121 1127
29. Molitch M. E., Steffes M., Sun W. et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care: 2010; 33 1536 1543
30. National Kidney Foundation/KDOQI Kidney Disease Outcome Quality Initiative Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis: 2007; 49 Suppl. 02 S12 S154
31. New J. P., Middleton R. J., Klebe B. et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med: 2007; 24 364 369 (Pubitemid 46452394)
32. Nishimura R., Dorman J. S., Bosnyak Z. et al. Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: A report from the Allegheny county registry. Am J Kid Dis: 2003; 42 117 124 (Pubitemid 36807660)
33. Out H. H., Can H., Spentzos D. et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care: 2007; 30 638 643 (Pubitemid 46354346)
34. Parving H. H., Brenner B. M., McMurray J. JV et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med: 2012; 367 2204 2213
35. Pergola P. E., Raskin P., Toto R. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med: 2011; 365 327 336
36. Perkins B. A., Ficociello L. H., Roshan B. et al. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney int: 2010; 77 57 64
37. Qualitätsbericht 2005 Disease-Management-Programme in Westfalen-Lippe DMP Diabetes mellitus Typ 2, Gemeinsame Einrichtung Disease-Management-Programme Westfalen-Lippe.
38. Raile K., Galler A., Hofer S. et al. Diabetic nephropathy in 27.805 children, adolescents and adults with type 1 diabetes. Diabetes Care: 2007; 30 2523 2528
39. Rao P. V., Lu X., Standley M. et al. Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care: 2007; 30 629 637 (Pubitemid 46354345)
40. Retnakaran R., Cull C. C., Torne K. I. et al. Risk factors for renal dysfunction in type 2 diabetes, U.K. Prospective Diabetes Study 74. Diabetes: 2006; 55 1833 1839
41. Schober-Halstenberg H-J. persönliche Kommunikation
42. Schneider R., Lopau K. Die transkutane Nierenbiopsie. Dtsch Med Wochenschr: 2010; 135 1247 1249
43. The ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med: 2010; 362 1575 1585
44. The Advance Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med: 2008; 358 2560 2572
45. The DCCT/EDIC Research Group Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med: 2011; 365 2366 2376
46. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med: 1993; 329 977 986
47. Tuttle K. R., Bakris G. L., Toto R. D. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care: 2005; 28 2686 2690 (Pubitemid 43951160)
48. Wenzel R. R., Littke T., Kuranof S. et al. Avosentan reduces albumin excretion in diabetes with macroalbuminuria. J Am Soc Nephrol: 2009; 20 655 664
49. de Zeeuw D., Agarwal R., Amdahl M. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (Vital study): a randomized controlled trial. Lancet: 2010; 376 1543 1551.